Content First was commissioned by the National Venture Capital Association (NVCA) to develop a study on the benefits of venture capital investment in the life sciences, Patient Capital: How Venture Capital Innovation Drives Revolutionary Medical Innovation.  The report was released in June 2007.

Patient Capital Key Findings

• The nation's most innovative medical breakthroughs have been brought to market by billions of dollars of venture capital investment in life sciences companies
• Venture backed life sciences companies include Boston Scientific, Amgen, Genentech, Genzyme, and Intuitive Surgical
• Impact of discoveries by venture capital backed life sciences companies saves millions of lives, improves medical procedures, reduces health care costs, and provides overall economic benefits to the U.S. economy